<code id='CC44CCACCD'></code><style id='CC44CCACCD'></style>
    • <acronym id='CC44CCACCD'></acronym>
      <center id='CC44CCACCD'><center id='CC44CCACCD'><tfoot id='CC44CCACCD'></tfoot></center><abbr id='CC44CCACCD'><dir id='CC44CCACCD'><tfoot id='CC44CCACCD'></tfoot><noframes id='CC44CCACCD'>

    • <optgroup id='CC44CCACCD'><strike id='CC44CCACCD'><sup id='CC44CCACCD'></sup></strike><code id='CC44CCACCD'></code></optgroup>
        1. <b id='CC44CCACCD'><label id='CC44CCACCD'><select id='CC44CCACCD'><dt id='CC44CCACCD'><span id='CC44CCACCD'></span></dt></select></label></b><u id='CC44CCACCD'></u>
          <i id='CC44CCACCD'><strike id='CC44CCACCD'><tt id='CC44CCACCD'><pre id='CC44CCACCD'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:Wikipedia    Page View:7484
          AP/Business Wire

          There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

          But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

          advertisement

          That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Christmas in the PICU brings some surprising joy
          Christmas in the PICU brings some surprising joy

          Calsmilesonher8thbirthday,justbeforeChristmas,afterbeingextubated.CourtesyMariaKefalasInthedaysleadi

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          Readout Newsletter: The latest on Moderna, Apellis, and Merck

          JakubPorzycki/NurPhotoviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetou